缬沙坦联合干扰素对慢性乙型肝炎患者AT-Ⅱ、TGF-β_1及组织病理学的影响

目的：探讨缬沙坦联合干扰素对慢性乙型肝炎患者血管紧张素Ⅱ（AT-Ⅱ）、转化生长因子-β1（TGF-β1）及肝组织病理学的影响。方法：经病理组织学确诊的50例慢性乙型肝炎患者随机分为治疗组及对照组,每组25例,两组均规范使用普通干扰素,治疗组加用缬沙坦80mg/d,治疗前及治疗48周后检测AT-Ⅱ及TGF-β_1水平,两组在疗程结束24周内分别有15例及13例患者复查肝组织病理检查。结果：应用缬沙坦治疗后血清AT-Ⅱ较治疗前升高,而血清TGF-β_1较治疗前下降,差异有统计学意义（P〈0.05）。血清两指标数值均与肝组织纤维化分级有相关性,差异有统计学意义（P〈0.05）。两组肝组织TGF-β_1治疗后表达均下降,而治疗组下降更明显,差异有统计学意义（P〈0.05）;两组肝组织炎症及纤维化评分均有改善,差异有统计学意义（P〈0.05）;治疗组改变更明显且不良反应少（P〈0.05）。结论：缬沙坦联合干扰素可以更有效地改善患者的组织学表现,严重不良反应少。

Impact of Valsartan in combination with Interferon on the chronic hepatitis B patients AT-Ⅱ,TGF-β1, and histopathology

Objective：To approach the impact of Valsartan in combination with Interferon on the chronic hepatitis B patients AT-Ⅱ,TGF-β1 and histopathology.Methods：The pathology confirmed 50 cases of chronic hepatitis B were randomly divided into treatment group and control group,each group had 25 patients.Both groups used the common standard interferon,treatment group was treated with Valsartan for 80 mg/d,detected the level of AT-Ⅱ and TGF-β1 before treatment and 48 weeks after treatment,reviewed liver histopathology 15 cases and 13 cases of two groups at the end of 24 weeks treatment.Results：After treatment with Valsartan,AT-Ⅱ was higher than that before treatment,and TGF-β1 was lower than that before treatment,the differences were significant（P0.05）.Two serum indexes were relevant to the degree of liver fibrosis,similarly there were significant differences（P0.05）.The TGF-β1 expression of two groups both had decreased after treatment（P0.05）,while the treatment group decreased more significantly（P0.05）,the difference was significant;the liver inflammation and fibrosis score of two groups both had improved（P0.05）,the difference was significant in the treatment group,and had more significantly fewer adverse reactions（P0.05）.Conclusion：Valsartan in combination with Interferon can more effectively improve the performance of patients with histology,and reduce adverse reactions.